

# Bernd Meibohm, Fcp

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9059309/publications.pdf>

Version: 2024-02-01

160  
papers

7,885  
citations

70961

41  
h-index

58464

82  
g-index

178  
all docs

178  
docs citations

178  
times ranked

11787  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetics of Monoclonal Antibodies. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 576-588.	1.3	503
2	Population Pharmacokinetics of Therapeutic Monoclonal Antibodies. <i>Clinical Pharmacokinetics</i> , 2010, 49, 633-659.	1.6	394
3	Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. <i>Nature Genetics</i> , 2011, 43, 1082-1090.	9.4	367
4	How Important Are Gender Differences in Pharmacokinetics?. <i>Clinical Pharmacokinetics</i> , 2002, 41, 329-342.	1.6	365
5	Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. , 1999, 16, 176-185.		275
6	Pharmacokinetic aspects of biotechnology products. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 2184-2204.	1.6	268
7	Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy. <i>AAPS Journal</i> , 2012, 14, 296-302.	2.2	262
8	Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Correlations of Therapeutic Peptides. <i>Clinical Pharmacokinetics</i> , 2013, 52, 855-868.	1.6	233
9	Genetic Ancestry in Lung-Function Predictions. <i>New England Journal of Medicine</i> , 2010, 363, 321-330.	13.9	230
10	Pharmacokinetics of Anthocyanins and Antioxidant Effects after the Consumption of Anthocyanin-Rich Açaí Juice and Pulp ( <i>Euterpe oleracea</i> Mart.) in Human Healthy Volunteers. <i>Journal of Agricultural and Food Chemistry</i> , 2008, 56, 7796-7802.	2.4	202
11	Genome-Wide Association Studies Identify <i>CHRNA5/3</i> and <i>HTR4</i> in the Development of Airflow Obstruction. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 622-632.	2.5	164
12	Population pharmacokinetic studies in pediatrics: Issues in design and analysis. <i>AAPS Journal</i> , 2005, 7, E475-E487.	2.2	163
13	Spectinomides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux. <i>Nature Medicine</i> , 2014, 20, 152-158.	15.2	160
14	The Clinical Pharmacokinetics of Phosphodiesterase-5 Inhibitors for Erectile Dysfunction. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 987-1003.	1.0	153
15	Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working Group. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 266-287.	2.3	147
16	The challenge of indication extrapolation for infliximab biosimilars. <i>Biologicals</i> , 2014, 42, 177-183.	0.5	138
17	The Effect of CYP3A5 and MDR1 Polymorphic Expression on Cyclosporine Oral Disposition in Renal Transplant Patients. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 555-564.	1.0	133
18	Pharmacokinetic/Pharmacodynamic Studies in Drug Product Development. <i>Journal of Pharmaceutical Sciences</i> , 2002, 91, 18-31.	1.6	130

#	ARTICLE	IF	CITATIONS
19	Genome-Wide Joint Meta-Analysis of SNP and SNP-by-Smoking Interaction Identifies Novel Loci for Pulmonary Function. <i>PLoS Genetics</i> , 2012, 8, e1003098.	1.5	130
20	Carvedilol therapy in pediatric patients with congestive heart failure: A study investigating clinical and pharmacokinetic parameters. <i>American Heart Journal</i> , 2002, 143, 916-922.	1.2	128
21	Characterizing the Impact of Renal Impairment on the Clinical Pharmacology of Biologics. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 54S-62S.	1.0	114
22	Discovery of Novel 2-Aryl-4-benzoyl-imidazoles Targeting the Colchicines Binding Site in Tubulin As Potential Anticancer Agents. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 7414-7427.	2.9	111
23	Tannic acid-inspired paclitaxel nanoparticles for enhanced anticancer effects in breast cancer cells. <i>Journal of Colloid and Interface Science</i> , 2019, 535, 133-148.	5.0	109
24	A microbiological assessment of novel nitrofuranyl amides as anti-tuberculosis agents. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1037-1045.	1.3	94
25	A tandem mass spectrometry assay for the simultaneous determination of acetaminophen, caffeine, phenytoin, ranitidine, and theophylline in small volume pediatric plasma specimens. <i>Clinica Chimica Acta</i> , 2008, 398, 105-112.	0.5	88
26	Concepts and Challenges in Quantitative Pharmacology and Model-Based Drug Development. <i>AAPS Journal</i> , 2008, 10, 552-559.	2.2	86
27	Is age-related decline in lean mass and physical function accelerated by obstructive lung disease or smoking?. <i>Thorax</i> , 2011, 66, 961-969.	2.7	85
28	Discovery of novel isoxazolines as anti-tuberculosis agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 6638-6642.	1.0	83
29	Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS. <i>Intensive Care Medicine</i> , 2020, 46, 2284-2296.	3.9	79
30	The influence of abdominal visceral fat on inflammatory pathways and mortality risk in obstructive lung disease. <i>American Journal of Clinical Nutrition</i> , 2012, 96, 516-526.	2.2	78
31	From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals. <i>Clinical and Experimental Immunology</i> , 2016, 184, 137-146.	1.1	76
32	Development of a Safe and Effective Pediatric Dosing Regimen for Sotalol Based on Population Pharmacokinetics and Pharmacodynamics in Children With Supraventricular Tachycardia. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1322-1330.	1.2	75
33	Population Pharmacokinetics of Cetuximab in Patients With Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 267-278.	1.0	74
34	Drug Development of Therapeutic Monoclonal Antibodies. <i>BioDrugs</i> , 2016, 30, 275-293.	2.2	68
35	The In Silico Child: Using Simulation to Guide Pediatric Drug Development and Manage Pediatric Pharmacotherapy. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 889-904.	1.0	63
36	<i>In vitro</i> pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB. <i>Future Medicinal Chemistry</i> , 2010, 2, 1355-1369.	1.1	54

#	ARTICLE	IF	CITATIONS
37	Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 511-522.	1.1	52
38	Large-Scale Genome-Wide Association Studies and Meta-Analyses of Longitudinal Change in Adult Lung Function. <i>PLoS ONE</i> , 2014, 9, e100776.	1.1	52
39	Dynamic Modeling of Cortisol Reduction after Inhaled Administration of Fluticasone Propionate. <i>Journal of Clinical Pharmacology</i> , 1996, 36, 938-941.	1.0	51
40	G2677T and C3435T Genotype and Haplotype Are Associated With Hepatic ABCB1 (MDR1) Expression. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 373-379.	1.0	49
41	Evaluation of Vancomycin Dosing Regimens in Preterm and Term Neonates Using Monte Carlo Simulations. <i>Pharmacotherapy</i> , 2012, 32, 408-419.	1.2	45
42	Evaluation of regional limb perfusion with amikacin using the saphenous, cephalic, and palmar digital veins in standing horses. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2013, 36, 236-240.	0.6	43
43	In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics. <i>Scientific Reports</i> , 2015, 5, 13985.	1.6	41
44	Antitubercular nitrofuranyl isoxazolines with improved pharmacokinetic properties. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 6063-6072.	1.4	39
45	Single- and Multiple-Dose Pharmacokinetics of Pioglitazone in Adolescents With Type 2 Diabetes. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 1137-1144.	1.0	38
46	Preclinical evaluation of SMM189, a cannabinoid receptor 2-specific inverse agonist. <i>Pharmacology Research and Perspectives</i> , 2015, 3, e00159.	1.1	38
47	Structure-Activity Relationships of Spectinamide Antituberculosis Agents: A Dissection of Ribosomal Inhibition and Native Efflux Avoidance Contributions. <i>ACS Infectious Diseases</i> , 2017, 3, 72-88.	1.8	36
48	Pharmacokinetics and Clinical Pharmacology of Monoclonal Antibodies in Pediatric Patients. <i>Paediatric Drugs</i> , 2020, 22, 199-216.	1.3	36
49	Effects of Alcohol on Human Carboxylesterase Drug Metabolism. <i>Clinical Pharmacokinetics</i> , 2015, 54, 627-638.	1.6	35
50	Pharmacokinetically-Guided Lead Optimization of Nitrofuranylamide Anti-Tuberculosis Agents. <i>AAPS Journal</i> , 2008, 10, 157-165.	2.2	34
51	Biopharmaceutics, Pharmacokinetics and Pharmacodynamics of Antituberculosis Drugs. <i>Current Medicinal Chemistry</i> , 2008, 15, 809-825.	1.2	34
52	A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria. <i>Tuberculosis</i> , 2009, 89, 378-385.	0.8	33
53	Clinical pharmacology of bispecific antibody constructs. <i>Journal of Clinical Pharmacology</i> , 2015, 55, S21-8.	1.0	33
54	Urinary metabolites from mango ( <i>Mangifera indica</i> L. cv. Keitt) galloyl derivatives and in vitro hydrolysis of gallotannins in physiological conditions. <i>Molecular Nutrition and Food Research</i> , 2016, 60, 542-550.	1.5	33

#	ARTICLE	IF	CITATIONS
55	Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2128-2138.	1.3	33
56	The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 555-64.	1.0	33
57	Modulation of Metoprolol Pharmacokinetics and Hemodynamics by Diphenhydramine Coadministration during Exercise Testing in Healthy Premenopausal Women. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 1172-1181.	1.3	31
58	Dependency of Cortisol Suppression on the Administration Time of Inhaled Corticosteroids. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 704-710.	1.0	30
59	Sustained plasma hepcidin suppression and iron elevation by Anticalinâ€derived hepcidin antagonist in cynomolgus monkey. <i>British Journal of Pharmacology</i> , 2018, 175, 1054-1065.	2.7	30
60	Pharmacokinetics of Monoclonal Antibodies. , 0, , 45-91.		30
61	The current role of model-based drug development. <i>Expert Opinion on Drug Discovery</i> , 2010, 5, 311-321.	2.5	29
62	Predictors of Mortality in Elderly Subjects with Obstructive Airway Disease: The PILE Score. <i>Annals of Epidemiology</i> , 2010, 20, 223-232.	0.9	29
63	Translational Biomarkers: from Preclinical to Clinical a Report of 2009 AAPS/ACCP Biomarker Workshop. <i>AAPS Journal</i> , 2011, 13, 274-283.	2.2	29
64	Challenges and considerations for development of therapeutic proteins in pediatric patients. <i>Journal of Clinical Pharmacology</i> , 2015, 55, S103-15.	1.0	29
65	Cross-Linked Polyphenol-Based Drug Nano-Self-Assemblies Engineered to Blockade Prostate Cancer Senescence. <i>ACS Applied Materials &amp; Interfaces</i> , 2019, 11, 38537-38554.	4.0	29
66	Genetic Ancestry-Smoking Interactions and Lung Function in African Americans: A Cohort Study. <i>PLoS ONE</i> , 2012, 7, e39541.	1.1	28
67	Effect of Ethanol on the Metabolic Characteristics of HIV-1 Integrase Inhibitor Elvitegravir and Elvitegravir/Cobicistat with CYP3A: An Analysis Using a Newly Developed LC-MS/MS Method. <i>PLoS ONE</i> , 2016, 11, e0149225.	1.1	27
68	Toward Optimal Treatment in Women: The Effect of Sex on Metoprololâ€Diphenhydramine Interaction. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 214-225.	1.0	26
69	Strategic Biomarkers for Drug Development in Treating Rare Diseases and Diseases in Neonates and Infants. <i>AAPS Journal</i> , 2013, 15, 447-454.	2.2	26
70	Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational and <i>In Vitro</i> Study. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 5469-5483.	2.5	26
71	Pharmacokinetic/Pharmacodynamic Evaluation of Systemic Effects of Flunisolide after Inhalation. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 893-903.	1.0	24
72	Pentacyclic Nitrofurans with In Vivo Efficacy and Activity against Nonreplicating Mycobacterium tuberculosis. <i>PLoS ONE</i> , 2014, 9, e87909.	1.1	24

#	ARTICLE	IF	CITATIONS
73	Translational PK/PD of anti-infective therapeutics. <i>Drug Discovery Today: Technologies</i> , 2016, 21-22, 41-49.	4.0	22
74	Expression Patterns of Organic Anion Transporting Polypeptides 1B1 and 1B3 Protein in Human Pediatric Liver. <i>Drug Metabolism and Disposition</i> , 2016, 44, 999-1004.	1.7	22
75	Tools for predicting the PK/PD of therapeutic proteins. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1115-1125.	1.5	21
76	A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant <i>Acinetobacter baumannii</i> . <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2869-2878.	2.9	21
77	Pharmacometrics as a Discipline Is Entering the "Industrialization" Phase: Standards, Automation, Knowledge Sharing, and Training Are Critical for Future Success. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 9S-19S.	1.0	20
78	Genetic variation in antioxidant enzymes, cigarette smoking, and longitudinal change in lung function. <i>Free Radical Biology and Medicine</i> , 2013, 63, 304-312.	1.3	20
79	Drug Clearance in Neonates: A Combination of Population Pharmacokinetic Modelling and Machine Learning Approaches to Improve Individual Prediction. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1435-1448.	1.6	20
80	Detection of MDR1 single nucleotide polymorphisms C3435T and G2677T using real-time polymerase chain reaction: MDR1 single nucleotide polymorphism genotyping assay. <i>AAPS PharmSci</i> , 2002, 4, 89-94.	1.3	19
81	Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 159-170.	1.3	19
82	Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinomamide 1599. <i>Pharmaceutical Research</i> , 2019, 36, 136.	1.7	19
83	Simple and sensitive assay for quantification of oseltamivir and its active metabolite oseltamivir carboxylate in human plasma using high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry: Improved applicability to pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2013, 72, 245-250.	1.4	18
84	A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1999, 27, 127-147.	0.6	17
85	Pharmacokinetics of intravenous amiodarone in children. <i>Archives of Disease in Childhood</i> , 2013, 98, 989-993.	1.0	17
86	Challenges and Opportunities for Increasing the Knowledge Base Related to Drug Biotransformation and Pharmacokinetics during Growth and Development. <i>Drug Metabolism and Disposition</i> , 2016, 44, 916-923.	1.7	17
87	Exposure-Response Relationships for Therapeutic Biologic Products. , 2006, , 295-327.		16
88	Aminomethyl spectinomycins as therapeutics for drug-resistant respiratory tract and sexually transmitted bacterial infections. <i>Science Translational Medicine</i> , 2015, 7, 288ra75.	5.8	16
89	Comparison of caffeine disposition following administration by oral solution (energy drink) and inspired powder (AeroShot) in human subjects. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2687-2694.	1.1	16
90	Real-time PCR-based genotyping assay for CXCR2 polymorphisms. <i>Clinica Chimica Acta</i> , 2004, 341, 93-100.	0.5	15

#	ARTICLE	IF	CITATIONS
91	Pattern Recognition in Pharmacokinetic Data Analysis. AAPS Journal, 2016, 18, 47-63.	2.2	15
92	Alterations in cellular pharmacokinetics and pharmacodynamics of elvitegravir in response to ethanol exposure in HIV-1 infected monocytic (U1) cells. PLoS ONE, 2017, 12, e0172628.	1.1	15
93	Developing a Gene Expression Model for Predicting Ventilator-Associated Pneumonia in Trauma Patients: A Pilot Study. PLoS ONE, 2012, 7, e42065.	1.1	13
94	Assessment of the Drug-Drug Interaction Potential Between Theacrine and Caffeine in Humans. Journal of Caffeine Research, 2017, 7, 95-102.	1.0	13
95	X-ray Crystallography-Guided Design, Antitumor Efficacy, and QSAR Analysis of Metabolically Stable Cyclopenta-Pyrimidinyl Dihydroquinoxalinone as a Potent Tubulin Polymerization Inhibitor. Journal of Medicinal Chemistry, 2021, 64, 13072-13095.	2.9	13
96	Pharmacokinetics of ponazuril after oral administration to healthy llamas (Lama glama). American Journal of Veterinary Research, 2011, 72, 1386-1389.	0.3	12
97	Genetic variation in antioxidant enzymes and lung function. Free Radical Biology and Medicine, 2012, 52, 1577-1583.	1.3	12
98	Limitations of Noncompartmental Pharmacokinetic Analysis of Biotech Drugs. , 2006, , 181-188.		11
99	Comparative Performance of Cell Life Span and Cell Transit Models for Describing Erythropoietic Drug Effects. AAPS Journal, 2011, 13, 650-661.	2.2	11
100	Phase II metabolic pathways of spectinamide antitubercular agents: a comparative study of the reactivity of 4-substituted pyridines to glutathione conjugation. MedChemComm, 2016, 7, 114-117.	3.5	11
101	Immunogenicity in Clinical Practice and Drug Development: When is it Significant?. Clinical and Translational Science, 2020, 13, 219-223.	1.5	11
102	Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric Patients. Pharmaceutics, 2020, 12, 908.	2.0	10
103	Discovery of N-(3,4-Dimethylphenyl)-4-(4-isobutylphenyl)-2,3,3a,4,5,9b-hexahydrofuro[3,2-c]quinoline-8-sulfonamide as a Potent Dual MDM2/XiAP Inhibitor. Journal of Medicinal Chemistry, 2021, 64, 1930-1950.		10
104	SYBR Green-based real-time PCR allelic discrimination assay for $\beta$ 2-adrenergic receptor polymorphisms. Analytical Biochemistry, 2005, 344, 292-294.	1.1	9
105	Pharmacokinetics of Peptides and Proteins. , 2006, , 15-43.		9
106	Dynamic time-kill curve characterization of spectinamide antibiotics 1445 and 1599 for the treatment of tuberculosis. European Journal of Pharmaceutical Sciences, 2019, 127, 233-239.	1.9	9
107	Use of Real-World Data and Pharmacometric Modeling in Support of Lacosamide Dosing in Pediatric Patients Under 4 Years of Age. Journal of Clinical Pharmacology, 2021, 61, 881-888.	1.0	9
108	Pediatric Dose Selection for Therapeutic Proteins. Journal of Clinical Pharmacology, 2021, 61, S193-S206.	1.0	9

#	ARTICLE	IF	CITATIONS
109	Clinical Drug Development of Cetuximab, a Monoclonal Antibody. , 0, , 353-371.		9
110	Pharmacokinetics and Pharmacodynamics of Peptide and Protein Therapeutics. , 2013, , 101-132.		9
111	Integration of Pharmacokinetics and Pharmacodynamics into the Drug Development of Pegfilgrastim, a Pegylated Protein. , 2006, , 373-393.		8
112	Comparative pharmacokinetics of spectinamide 1599 after subcutaneous and intrapulmonary aerosol administration in mice. Tuberculosis, 2019, 114, 119-122.	0.8	8
113	Preclinical Evaluation of Inhalational Spectinamide-1599 Therapy against Tuberculosis. ACS Infectious Diseases, 2021, 7, 2850-2863.	1.8	8
114	Time to â€œMind the Gapâ€™ in novel small molecule drug discovery for direct-acting antivirals for SARS-CoV-2. Current Opinion in Virology, 2021, 50, 1-7.	2.6	8
115	Ethanol Lock Therapy. Annals of Pharmacotherapy, 2015, 49, 431-436.	0.9	7
116	Influence of Ethanol on Darunavir Hepatic Clearance and Intracellular PK/PD in HIV-Infected Monocytes, and CYP3A4-Darunavir Interactions Using Inhibition and in Silico Binding Studies. Pharmaceutical Research, 2017, 34, 1925-1933.	1.7	7
117	Pharmacometric Applications and Challenges in the Development of Therapeutic Antibodies in Immuno-Oncology. Current Pharmacology Reports, 2018, 4, 285-291.	1.5	7
118	Model-Based Exposure-Response Assessment for Spectinamide 1810 in a Mouse Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0174420.	1.4	7
119	The Role of Pharmacokinetics and Pharmacodynamics in the Development of Biotech Drugs. , 2006, , 1-13.		6
120	Cognitive Impairment and Medication Complexity in Community-Living Older Adults: The Health, Aging and Body Composition Study. Journal of Pharmacy Technology, 2012, 28, 156-162.	0.5	6
121	Creatinineâ€¢Based Vancomycin Dosing Regimens in Neonates: There Is More to Consider Than the Variation in Drug Assay. Pharmacotherapy, 2012, 32, e174; discussion e175.	1.2	6
122	Regulatory and Ethical Issues in Pediatric Clinical Research: Recommendations From a Panel Discussion. Journal of Clinical Pharmacology, 2017, 57, 943-946.	1.0	6
123	Effective Removal of Dabigatran by Idarucizumab or Hemodialysis: A Physiologically Based Pharmacokinetic Modeling Analysis. Clinical Pharmacokinetics, 2020, 59, 809-825.	1.6	6
124	Pharmacokinetics and Pharmacodynamics of Antisense Oligonucleotides. , 0, , 93-120.		6
125	Protein Engineering for Improved Pharmacologic Characteristics of Established Monoclonal Antibody-Based Therapeutics. Clinical Pharmacokinetics, 2014, 53, 863-864.	1.6	5
126	Tissue Penetration of a Novel Spectinamide Antibiotic for the Treatment of Tuberculosis. AAPS Journal, 2016, 18, 788-791.	2.2	5



#	ARTICLE	IF	CITATIONS
127	Immune Suppression During Preclinical Drug Development Mitigates Immunogenicity-Mediated Impact on Therapeutic Exposure. <i>AAPS Journal</i> , 2017, 19, 447-455.	2.2	5
128	Primary Lung Dendritic Cell Cultures to Assess Efficacy of Spectinamide-1599 Against Intracellular <i>Mycobacterium tuberculosis</i> . <i>Frontiers in Microbiology</i> , 2018, 9, 1895.	1.5	5
129	Pharmacokinetics and Pharmacodynamics of Therapeutic Peptides and Proteins. , 2019, , 105-137.		5
130	Custom-Tailored Pharmacokinetics and Pharmacodynamics via Chemical Modifications of Biotech Drugs. , 0, , 271-294.		5
131	Colchicine-Binding Site Agent CH-2-77 as a Potent Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1103-1114.	1.9	5
132	LC/MS/MS in drug development: targeting the brain. <i>BioTechniques</i> , 2005, 38, S19-S23.	0.8	4
133	Population Pharmacokinetic/Pharmacodynamic Analyses as the Basis for Dosing of Therapeutic Monoclonal Antibodies. <i>Clinical Pharmacokinetics</i> , 2011, 50, 823-824.	1.6	4
134	Response to “Physiologically Based Pharmacokinetic Modeling at the Extremes of Age”. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 93, 149-149.	2.3	4
135	Novel Endogenous Glycan Therapy for Retinal Diseases: Safety, In Vitro Stability, Ocular Pharmacokinetic Modeling, and Biodistribution. <i>AAPS Journal</i> , 2014, 16, 311-323.	2.2	4
136	Study Design and Simulation Approach. <i>Handbook of Experimental Pharmacology</i> , 2011, 205, 125-148.	0.9	3
137	Pharmacokinetics of a combination of $\Delta^9$ -tetrahydrocannabinol and celecoxib in a porcine model of hemorrhagic shock. <i>Biopharmaceutics and Drug Disposition</i> , 2011, 32, 89-98.	1.1	3
138	Essential criteria for pharmacokinetic studies supporting bioequivalence of inhaled tiotropium bromide products. <i>Clinical Pharmacology in Drug Development</i> , 2016, 5, 52-56.	0.8	3
139	Core Entrustable Professional Activities in Clinical Pharmacology for Entering Residency: Biologics. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 947-955.	1.0	3
140	Pharmacokinetics and Pharmacodynamics of Biotech Drugs. , 2005, , 145-172.		2
141	Long Pulmonary Residence Time and Plasma Half-Life of Tiotropium: Implications for Pharmacokinetic Bioequivalence Studies. <i>Clinical Drug Investigation</i> , 2017, 37, 705-707.	1.1	2
142	Sterilization of <i>Mycobacterium tuberculosis</i> infected samples using methanol preserves anti-tuberculosis drugs for subsequent pharmacological testing studies. <i>Tuberculosis</i> , 2019, 117, 52-55.	0.8	2
143	Core Entrustable Professional Activities in Clinical Pharmacology for Entering Residency: Common Problem Drugs and How to Prescribe Them. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 915-922.	1.0	2
144	Preclinical and Clinical Drug Development of Tasidotin, a Depsi-Pentapeptide Oncolytic Agent. , 0, , 329-351.		2

